Michael Latwis, corporate analyst at Decision Resources, is available to discuss the announcement made on June 11, 2008 by Daiichi Sankyo that it will buy control of India's Ranbaxy Laboratories Ltd. for as much as $4.6 billion. The acquisition, if completed, is expected to make Daiichi Sankyo a major player in the generic drug industry, and provide important research and manufacturing capabilities in the low cost Indian market.

  Mr. Latwis can discuss how this deal, if completed, will:    -- Help Daiichi Sankyo diversify its business within a different segment      of the pharmaceutical industry as, following years of divestments in      unrelated businesses, Daiichi Sankyo will now participate in a full      range of drug product offerings through branded, generic and      over-the-counter product lines   -- Allow Daiichi Sankyo to benefit from an upcoming wave of patent      expirations in the U.S. and European markets, while also promoting      generic products in the under-penetrated Japanese region   -- Support Daiichi Sankyo's geographic expansion plans, particularly in      fast-growing emerging markets such as India   -- Leverage Ranbaxy's research resources and manufacturing capabilities,      particularly within the Indian market   -- Maintain Ranbaxy's independence as a subsidiary of Daiichi Sankyo by      retaining, as is currently proposed, Ranbaxy Chief Executive Officer      Malvinder Singh   -- Enable Ranbaxy, through the support of a large globally-established      pharmaceutical company, to further implement their own drug development      ambitions   -- Provide the controlling family of Ranbaxy with an attractive      opportunity to monetize their stake in the company  

To speak with Mr. Latwis, please contact Christopher Comfort at 781-296-2597 or ccomfort@dresources.com.

  For more information, contact:   Elizabeth Marshall   781-296-2563   emarshall@dresources.com    About Decision Resources 

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

PRNewswire -- June 11

SOURCE: Decision Resources

A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market

View Now